The U.S. Food and Drug Administration (FDA) has approved Romark’s manufacturing facility in Manati, Puerto Rico for the production of Alinia (nitazoxanide) tablets, 500 mg and Alinia (nitazoxanide) for Oral Suspension, 100 mg/5mL in the U.S. market.   The new facility encompasses approximately 35,000 square feet and is equipped with suites and equipment to produce tablets, powders and other oral solid dosage forms.   “This is a major milestone for us, as it allows us to expand our capacity...